CytomX Therapeutics develops Probody⢠therapeutics for the treatment of cancer. Probody therapeutics are fully recombinant masked antibodies that are designed to remain inert in healthy tissue but become activated specifically in the tumor microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, potentially unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology. Source
No articles found.
At Achillion, we are driven to transform the lives of patients and families affect...
At Achillion, we are driven to transform the li...
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on deve...
Aptevo Therapeutics Inc. is a clinical-stage bi...
Autolus is a clinical-stage, biopharmaceutical company, focused on the development...
Autolus is a clinical-stage, biopharmaceutical ...
Generex Biotechnology is an integrated healthcare holding company with end-to-end ...
Generex Biotechnology is an integrated healthca...
We have used biochemical, molecular & cell biology and in vivo models to screen, i...
We have used biochemical, molecular & cell biol...
Proteon Therapeutics is working to deliver a new future for patients and families ...
Proteon Therapeutics is working to deliver a ne...
We are a biopharmaceutical company dedicated to the development of programmed cell...
We are a biopharmaceutical company dedicated to...
Join the National Investor Network and get the latest information with your interests in mind.